Dapagliflozin
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
<scene name='10/1001152/Cv/2'>Human SGLT2-MAP17 complex with Dapagliflozin</scene> ([[8hez]]). | <scene name='10/1001152/Cv/2'>Human SGLT2-MAP17 complex with Dapagliflozin</scene> ([[8hez]]). | ||
| + | |||
| + | <scene name='10/1001152/Cv/3'>Dapagliflozin binding site</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 13:02, 25 January 2024
| |||||||||||
References
- ↑ Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. PMID:32970396 doi:10.1056/NEJMoa2024816
- ↑ Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. PMID:30990260 doi:10.1056/NEJMoa1811744
